2.19

0.92% 0.02

After Hours: 2.19

Mersana Therapeutics Inc (MRSN)

Overview News Price History Option Chain Financials Discussions Forecast

Mersana Therapeutics Inc stock is traded at $2.19, with a volume of 608.65K. It is up +0.92% in the last 24 hours and up +15.26% over the past month. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Previous Close:

$2.17

Open:

$2.18

24h Volume:

608.65K

Relative Volume:

0.59

Market Cap:

$270.54M

Revenue:

$36.86M

Net Income/Loss:

$-171.67M

P/E Ratio:

-1.0735

EPS:

-2.04

Net Cash Flow:

$-171.05M

1W Performance:

-1.35%

1M Performance:

+15.26%

6M Performance:

-7.98%

1Y Performance:

+43.14%

1-Day Range:

$2.11

$2.226

1-Week Range:

$1.92

$2.29

52-Week Range:

$1.22

$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name

Mersana Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

617-498-0020

Address

840 MEMORIAL DRIVE, CAMBRIDGE

Employee

123

Twitter

@MersanaADC

Next Earnings Date

2024-11-05

Latest SEC Filings

MRSN's Discussions on Twitter

Compare MRSN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRSN Mersana Therapeutics Inc	2.19	270.54M	36.86M	-171.67M	-171.05M	-2.04
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-15-24	Resumed	Citigroup	Buy
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform
Dec-04-23	Upgrade	Citigroup	Neutral → Buy
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral
Jun-15-23	Initiated	Guggenheim	Buy
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-23	Initiated	Citigroup	Buy
Nov-21-22	Initiated	Truist	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Aug-30-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Apr-29-20	Initiated	BTIG Research	Buy
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Mar-11-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-08-18	Initiated	Robert W. Baird	Outperform
Mar-19-18	Downgrade	JP Morgan	Overweight → Neutral

View All

Mersana Therapeutics Inc Stock (MRSN) Latest News

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Cash Flow from Investing : €-17.49 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Forward Dividend Yield % : 0.00% (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024